PT2646466T - Meios e métodos para produzir anticorpos de alta afinidade - Google Patents

Meios e métodos para produzir anticorpos de alta afinidade

Info

Publication number
PT2646466T
PT2646466T PT117912840T PT11791284T PT2646466T PT 2646466 T PT2646466 T PT 2646466T PT 117912840 T PT117912840 T PT 117912840T PT 11791284 T PT11791284 T PT 11791284T PT 2646466 T PT2646466 T PT 2646466T
Authority
PT
Portugal
Prior art keywords
methods
high affinity
producing high
affinity antibodies
antibodies
Prior art date
Application number
PT117912840T
Other languages
English (en)
Inventor
Beaumont Tim
Jeroen Kwakkenbos Mark
Spits Hergen
Quirinus Bakker Adrianus
Wagner Koen
Original Assignee
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv filed Critical Aimm Therapeutics Bv
Publication of PT2646466T publication Critical patent/PT2646466T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60P—VEHICLES ADAPTED FOR LOAD TRANSPORTATION OR TO TRANSPORT, TO CARRY, OR TO COMPRISE SPECIAL LOADS OR OBJECTS
    • B60P1/00—Vehicles predominantly for transporting loads and modified to facilitate loading, consolidating the load, or unloading
    • B60P1/04—Vehicles predominantly for transporting loads and modified to facilitate loading, consolidating the load, or unloading with a tipping movement of load-transporting element
    • B60P1/28—Tipping body constructions
    • B60P1/283—Elements of tipping devices
    • B60P1/286—Loading buckets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PT117912840T 2010-12-02 2011-12-02 Meios e métodos para produzir anticorpos de alta afinidade PT2646466T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10193562 2010-12-02
US41990910P 2010-12-06 2010-12-06

Publications (1)

Publication Number Publication Date
PT2646466T true PT2646466T (pt) 2017-06-07

Family

ID=43837992

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117912840T PT2646466T (pt) 2010-12-02 2011-12-02 Meios e métodos para produzir anticorpos de alta afinidade

Country Status (15)

Country Link
US (2) US9206247B2 (pt)
EP (1) EP2646466B1 (pt)
JP (1) JP6013356B2 (pt)
CN (1) CN103429615B (pt)
AU (1) AU2011334867B2 (pt)
BR (1) BR112013013573B1 (pt)
CA (1) CA2819070C (pt)
DK (1) DK2646466T3 (pt)
ES (1) ES2626671T3 (pt)
HU (1) HUE033141T2 (pt)
NZ (1) NZ611600A (pt)
PL (1) PL2646466T3 (pt)
PT (1) PT2646466T (pt)
RU (1) RU2585153C2 (pt)
WO (1) WO2012072814A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ600075A (en) 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
HUE033141T2 (en) 2010-12-02 2017-11-28 Aimm Therapeutics Bv Instruments and methods for producing high affinity antibodies
US10017739B2 (en) * 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2015037992A1 (en) * 2013-09-11 2015-03-19 Aimm Therapeutics B.V. Parechovirus specific antibodies
US10825548B2 (en) * 2013-12-02 2020-11-03 Carterra, Inc. Systems and methods of sensing and analyzing antibody blocking interactions
US20170009205A1 (en) * 2013-12-23 2017-01-12 Aimm Therapeutics B.V. Ex vivo antibody production
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
EP3218396B1 (en) 2014-11-14 2022-12-28 Regeneron Pharmaceuticals, Inc. Method for generating high affinity antibodies
CN105296436B (zh) * 2015-11-19 2018-06-08 江南大学 一株二叔丁基对甲酚单克隆抗体杂交瘤细胞株及其应用
EP3548622A1 (en) 2016-12-02 2019-10-09 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
WO2018205917A1 (en) * 2017-05-08 2018-11-15 Tsinghua University Novel method for producing antibodies

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997764A (en) 1987-04-23 1991-03-05 New York University Transformation of human B-lympocytes with Epstein Barr virus and c-myc containing vectors
ATE132190T1 (de) 1988-02-26 1996-01-15 Worcester Found Ex Biology Hemmung von htlv-iii durch exogene oligonukleotide
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
WO1994007367A1 (en) 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
CA2146364A1 (en) 1992-10-05 1994-04-14 Sudhir Agrawal Therapeutic anti-hiv oligonucleotide and pharmaceutical
WO1994017086A1 (en) 1993-01-25 1994-08-04 Apollon, Inc. Gene regulation by targeting putative intramolecular triple helix
US5550019A (en) 1993-05-26 1996-08-27 La Jolla Cancer Research Foundation Methods of identifying compounds which alter apoptosis
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
CA2170980A1 (en) 1993-09-03 1995-03-09 James Mule Genetically modified human hematopoietic stem cells and their progeny
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6001558A (en) 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
EP1214399B1 (en) 1999-09-08 2007-07-11 Genetrol Biotherapeutics High level cytokine production with enhanced cell viability
EP1083230A1 (en) 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US7122180B2 (en) 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050009180A1 (en) 2001-12-10 2005-01-13 Lili Yang Method for the generation of antigen-specific lymphocytes
AU2002359666A1 (en) 2001-12-10 2003-06-23 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
SI1458855T1 (sl) 2001-12-18 2012-08-31 Cancer Rec Tech Ltd Postopek za pripravo proliferacijskih in diferenciacijskih celičnih linij
WO2003068819A1 (en) 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
CA2479530A1 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
WO2004040969A1 (ja) * 2002-11-07 2004-05-21 Kumamoto Technology & Industry Foundation Ｇａｎｐ導入トランスジェニック哺乳動物及びその利用
US20060167230A1 (en) * 2003-01-20 2006-07-27 Takaki Koga Anti-pci neutralizing antibody
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
ES2340280T3 (es) 2003-03-14 2010-06-01 Wyeth Llc Anticuerpos dirigidos contra el receptor de il-21 humano y uso de los mismos.
PL2149585T3 (pl) * 2003-11-04 2014-01-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał monoklonalnych anty-CD40
GB2422845B (en) 2003-11-19 2007-08-01 Us Gov Health & Human Serv Method of inducing memory B cell development and terminal differentiation
GB0327384D0 (en) 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
WO2005123923A2 (en) 2004-06-17 2005-12-29 Wolfgang Hillen Inducer specific tetracycline repressor proteins and methods of use thereof
EP1627563A1 (en) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for producing a stabilized cell of interest
EP1647595A1 (en) 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nucleic acids against viruses, in particular HIV
US7393923B2 (en) 2004-11-08 2008-07-01 The Regents Of The University Of California Red-shifted fluorescent proteins mPlum and mRaspberry and polynucleotides encoding the same
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
EP1891209A1 (en) 2005-06-06 2008-02-27 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for generating a t cell against an antigen of interest.
JP4482693B2 (ja) * 2005-08-29 2010-06-16 国立大学法人 岡山大学 抗体産生細胞の特異的選択方法
DK1954811T3 (da) 2005-11-17 2011-07-04 Tet Systems Gmbh & Co Kg Inducerbare ekspressionssystemer
NZ600075A (en) 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
WO2008103475A1 (en) 2007-02-20 2008-08-28 Anaptysbio, Inc. Somatic hypermutation systems
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8999707B2 (en) * 2008-01-28 2015-04-07 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
ES2341419B1 (es) 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona Wnt1 como biomarcador de daño renal.
JP5683566B2 (ja) 2009-04-03 2015-03-11 メディカル リサーチ カウンシル 活性化誘導シチジンデアミナーゼ（ａｉｄ）の変異体及び使用方法
DK2454283T3 (en) * 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
MX350234B (es) 2009-07-15 2017-08-30 Aimm Therapeutics Bv Compuestos de enlace especificos de bacterias gram-positivas.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RU2540020C2 (ru) * 2009-10-06 2015-01-27 Медиммьюн Лтд Молекула, специфически связывающаяся с rsv
HUE033141T2 (en) 2010-12-02 2017-11-28 Aimm Therapeutics Bv Instruments and methods for producing high affinity antibodies
KR20140112495A (ko) 2011-12-02 2014-09-23 에임 쎄라퓨틱스 비.브이. 인플루엔자 a 바이러스 특이적 항체
US20170009205A1 (en) * 2013-12-23 2017-01-12 Aimm Therapeutics B.V. Ex vivo antibody production

Also Published As

Publication number Publication date
BR112013013573B1 (pt) 2021-04-27
CA2819070A1 (en) 2012-06-07
ES2626671T3 (es) 2017-07-25
JP6013356B2 (ja) 2016-10-25
CN103429615B (zh) 2018-03-16
RU2013130006A (ru) 2015-01-10
DK2646466T3 (en) 2017-06-06
JP2014500726A (ja) 2014-01-16
HUE033141T2 (en) 2017-11-28
US9206247B2 (en) 2015-12-08
US20130331552A1 (en) 2013-12-12
NZ611600A (en) 2015-02-27
RU2585153C2 (ru) 2016-05-27
WO2012072814A1 (en) 2012-06-07
CN103429615A (zh) 2013-12-04
EP2646466A1 (en) 2013-10-09
PL2646466T3 (pl) 2017-09-29
BR112013013573A2 (pt) 2016-10-11
EP2646466B1 (en) 2017-03-29
AU2011334867A1 (en) 2013-06-20
US20160096881A1 (en) 2016-04-07
CA2819070C (en) 2020-03-10
AU2011334867B2 (en) 2016-10-13
US9969795B2 (en) 2018-05-15

Similar Documents

Publication Publication Date Title
PT2646466T (pt) Meios e métodos para produzir anticorpos de alta afinidade
IL240898A0 (en) Antibodies against a5c and methods of using the antibodies
IL249501A0 (en) A process for creating antibodies
IL223018A0 (en) Method for preparing antibodies having improved properties
EP2534178A4 (en) THERAPEUTIC PROCEDURES WITH TI-CD200 ANTIBODIES
EP2624066A4 (en) LOADING ELEMENT AND METHOD FOR THE MANUFACTURE THEREOF
GB201115529D0 (en) Antibodies, uses and methods
GB201115280D0 (en) Antibodies, uses and methods
IL214433A0 (en) Anti-fgfr3 antibodies and methods using same
EP2545104A4 (en) PARTICLES AND METHOD FOR THE PRODUCTION THEREOF
EP2613203A4 (en) LOADING ELEMENT AND PROCESS FOR PRODUCING THE SAME
HK1180345A1 (zh) 篩選抗體的方法
EP2628053A4 (en) TONER AND METHOD FOR THE PRODUCTION THEREOF
EP2558587A4 (en) METHOD FOR DISPLAYING ANTIBODIES
EP2542706A4 (en) Apparatus and methods for producing direct reduced iron
EP2559781A4 (en) SPRING AND METHOD FOR MANUFACTURING THE SAME
IL222184A (en) Amino-pyridine-n- oxides are converted and methods of preparation
HK1158029A1 (en) Cystine-containing complex and method for producing the same
EP2653541A4 (en) PROCESS FOR THE PRODUCTION OF PROTEINS
IL266073B (en) Heterodimeric antibody fccontaining proteins and methods for production thereof